L
Laurence Collette
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 281
Citations - 37642
Laurence Collette is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 78, co-authored 276 publications receiving 33811 citations. Previous affiliations of Laurence Collette include VU University Amsterdam & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
Anthony V. D'Amico,James W. Denham,Michel Bolla,Laurence Collette,David Lamb,Keen Hun Tai,Allison Steigler,Ming-Hui Chen +7 more
TL;DR: The study evaluated whether the use of 3 years as compared with 6 months of androgen suppression therapy (AST) combined with external beam radiation therapy (RT) in the treatment of high‐risk prostate cancer was associated with prolonged survival in advanced age men.
Journal ArticleDOI
Impact of a boost dose of 16 GY on the local control and cosmesis in patients with early breast cancer: The EORTC ‘boost versus no boost’ trial
Harry Bartelink,Laurence Collette,Alain Fourquet,Jean-Claude Horiot,Jos J. Jager,Johannes L. Peterse,Marianne Pierart,P.M Poortmans,H. Struikmans,W. Van den Bogaert +9 more
Journal ArticleDOI
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie,Meredith M. Regan,Marc Buyse,Susan Halabi,Philip W. Kantoff,Oliver Sartor,Howard R. Soule,Donald A. Berry,Noel W. Clarke,Laurence Collette,Anthony V. D'Amico,Richard De Abreu Lourenco,James J. Dignam,Mario A. Eisenberger,Nicholas D. James,Karim Fizazi,Silke Gillessen,Yohann Loriot,Nicolas Mottet,Wendy R. Parulekar,Howard M. Sandler,Daniel E. Spratt,Matthew R. Sydes,Bertrand Tombal,Scott Williams,Christopher Sweeney +25 more
TL;DR: EFS is a weak surrogate for OS and is not suitable for use as an intermediate clinical end point to substitute for OS to accelerate phase III (neo)adjuvant trials of prostate cancer therapies for primary radiation therapy-based trials.
Journal ArticleDOI
Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials
Maria Antonietta Gambacorta,Carlotta Masciocchi,Giuditta Chiloiro,E. Meldolesi,Gabriella Macchia,Johan van Soest,Fenke Peters,Laurence Collette,Jean Pierre Gerard,Samuel Y Ngan,C. Claus Rödel,Andrea Damiani,Andre Dekker,Vincenzo Valentini +13 more
TL;DR: It is suggested that the best time to achieve pCR in LARC is at 10 weeks, considering that the lengthening of SI is not detrimental concerning postoperative complications or survival outcomes.
Journal ArticleDOI
Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study
Michel Bolla,Laurence Collette,G. van Tienhoven,Padraig Warde,Jean-Bernard Dubois,R.O. Mirimanoff,Guy Storme,Jean-Jacques Bernier,Abraham Kuten,Marianne Pierart +9 more